Continuous glucose monitoring is becoming increasingly more widespread for the routine care of people with type 1 diabetes mellitus and may eventually be used in closed-loop artificial b-cell systems. The current “state of the art” of this technology, including accuracy, performance in clinical trials, limitations, and recommendations for use, is discussed for the two currently approved continuous glucose monitoring devices.